VA BENEFITS REFERENCE
The Respiratory System: Shared Criteria For DC 6825 Through 6833
Read the respiratory system criteria for DC 6825 through 6833: 9 listed codes, their distinct instructions, shared formulas and official notes.
Published criteria from 38 CFR 4.97, current through 2026-10-22. Historical decisions may require a different version. This reference does not diagnose a condition or determine an evaluation.
The Respiratory System · All Diagnostic Codes
DC 6825: Diffuse Interstitial Fibrosis (Interstitial Pneumonitis, Fibrosing Alveolitis)
Diagnostic code 6825 addresses Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis). Read its specific instructions together with any shared formula, notes and linked provisions. These criteria describe evaluation after the applicable entitlement requirements are met; this reference does not diagnose a condition or determine a claim.
| Rating | |
|---|---|
| 6825 Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis). | |
| 1 Review for entitlement to special monthly compensation under § 3.350 of this chapter. | |
Read the shared provisions referenced by this code: Interstitial Lung Formula.
What The Criteria Measure
- Does the decision identify diagnostic code 6825, and does the medical record describe the condition named by this code?
- Are the required clinical measurements, testing methods and any stated exceptions documented by a qualified clinician?
- Do records identify the treatment, procedure and relevant dates that the provision actually distinguishes?
- Have the code-specific notes and cross-references been read before comparing any listed evaluation?
Related Public DBQs
Editorial subject matches, not official VA code-to-form assignments. Read the form scope and clinician instructions.
Regulatory Cross-References
- DC 6826: Desquamative interstitial pneumonitis
- DC 6827: Pulmonary alveolar proteinosis
- DC 6828: Eosinophilic granuloma of lung
- DC 6829: Drug-induced pulmonary pneumonitis and fibrosis
- DC 6830: Radiation-induced pulmonary pneumonitis and fibrosis
- DC 6831: Hypersensitivity pneumonitis (extrinsic allergic alveolitis)
- DC 6832: Pneumoconiosis (silicosis, anthracosis, etc.)
- DC 6833: Asbestosis
DC 6826: Desquamative Interstitial Pneumonitis
Diagnostic code 6826 addresses Desquamative interstitial pneumonitis. Read its specific instructions together with any shared formula, notes and linked provisions. These criteria describe evaluation after the applicable entitlement requirements are met; this reference does not diagnose a condition or determine a claim.
| Rating | |
|---|---|
| 6826 Desquamative interstitial pneumonitis. | |
| 1 Review for entitlement to special monthly compensation under § 3.350 of this chapter. | |
Read the shared provisions referenced by this code: Interstitial Lung Formula.
What The Criteria Measure
- Does the decision identify diagnostic code 6826, and does the medical record describe the condition named by this code?
- Are the required clinical measurements, testing methods and any stated exceptions documented by a qualified clinician?
- Do records identify the treatment, procedure and relevant dates that the provision actually distinguishes?
- Have the code-specific notes and cross-references been read before comparing any listed evaluation?
Related Public DBQs
Editorial subject matches, not official VA code-to-form assignments. Read the form scope and clinician instructions.
Regulatory Cross-References
- DC 6825: Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis)
- DC 6827: Pulmonary alveolar proteinosis
- DC 6828: Eosinophilic granuloma of lung
- DC 6829: Drug-induced pulmonary pneumonitis and fibrosis
- DC 6830: Radiation-induced pulmonary pneumonitis and fibrosis
- DC 6831: Hypersensitivity pneumonitis (extrinsic allergic alveolitis)
- DC 6832: Pneumoconiosis (silicosis, anthracosis, etc.)
- DC 6833: Asbestosis
DC 6827: Pulmonary Alveolar Proteinosis
Diagnostic code 6827 addresses Pulmonary alveolar proteinosis. Read its specific instructions together with any shared formula, notes and linked provisions. These criteria describe evaluation after the applicable entitlement requirements are met; this reference does not diagnose a condition or determine a claim.
| Rating | |
|---|---|
| 6827 Pulmonary alveolar proteinosis. | |
| 1 Review for entitlement to special monthly compensation under § 3.350 of this chapter. | |
Read the shared provisions referenced by this code: Interstitial Lung Formula.
What The Criteria Measure
- Does the decision identify diagnostic code 6827, and does the medical record describe the condition named by this code?
- Are the required clinical measurements, testing methods and any stated exceptions documented by a qualified clinician?
- Do records identify the treatment, procedure and relevant dates that the provision actually distinguishes?
- Have the code-specific notes and cross-references been read before comparing any listed evaluation?
Related Public DBQs
Editorial subject matches, not official VA code-to-form assignments. Read the form scope and clinician instructions.
Regulatory Cross-References
- DC 6825: Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis)
- DC 6826: Desquamative interstitial pneumonitis
- DC 6828: Eosinophilic granuloma of lung
- DC 6829: Drug-induced pulmonary pneumonitis and fibrosis
- DC 6830: Radiation-induced pulmonary pneumonitis and fibrosis
- DC 6831: Hypersensitivity pneumonitis (extrinsic allergic alveolitis)
- DC 6832: Pneumoconiosis (silicosis, anthracosis, etc.)
- DC 6833: Asbestosis
DC 6828: Eosinophilic Granuloma Of Lung
Diagnostic code 6828 addresses Eosinophilic granuloma of lung. Read its specific instructions together with any shared formula, notes and linked provisions. These criteria describe evaluation after the applicable entitlement requirements are met; this reference does not diagnose a condition or determine a claim.
| Rating | |
|---|---|
| 6828 Eosinophilic granuloma of lung. | |
| 1 Review for entitlement to special monthly compensation under § 3.350 of this chapter. | |
Read the shared provisions referenced by this code: Interstitial Lung Formula.
What The Criteria Measure
- Does the decision identify diagnostic code 6828, and does the medical record describe the condition named by this code?
- Are the required clinical measurements, testing methods and any stated exceptions documented by a qualified clinician?
- Do records identify the treatment, procedure and relevant dates that the provision actually distinguishes?
- Have the code-specific notes and cross-references been read before comparing any listed evaluation?
Related Public DBQs
Editorial subject matches, not official VA code-to-form assignments. Read the form scope and clinician instructions.
Regulatory Cross-References
- DC 6825: Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis)
- DC 6826: Desquamative interstitial pneumonitis
- DC 6827: Pulmonary alveolar proteinosis
- DC 6829: Drug-induced pulmonary pneumonitis and fibrosis
- DC 6830: Radiation-induced pulmonary pneumonitis and fibrosis
- DC 6831: Hypersensitivity pneumonitis (extrinsic allergic alveolitis)
- DC 6832: Pneumoconiosis (silicosis, anthracosis, etc.)
- DC 6833: Asbestosis
DC 6829: Drug-Induced Pulmonary Pneumonitis And Fibrosis
Diagnostic code 6829 addresses Drug-induced pulmonary pneumonitis and fibrosis. Read its specific instructions together with any shared formula, notes and linked provisions. These criteria describe evaluation after the applicable entitlement requirements are met; this reference does not diagnose a condition or determine a claim.
| Rating | |
|---|---|
| 6829 Drug-induced pulmonary pneumonitis and fibrosis. | |
| 1 Review for entitlement to special monthly compensation under § 3.350 of this chapter. | |
Read the shared provisions referenced by this code: Interstitial Lung Formula.
What The Criteria Measure
- Does the decision identify diagnostic code 6829, and does the medical record describe the condition named by this code?
- Are the required clinical measurements, testing methods and any stated exceptions documented by a qualified clinician?
- Do records identify the treatment, procedure and relevant dates that the provision actually distinguishes?
- Have the code-specific notes and cross-references been read before comparing any listed evaluation?
Related Public DBQs
Editorial subject matches, not official VA code-to-form assignments. Read the form scope and clinician instructions.
Regulatory Cross-References
- DC 6825: Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis)
- DC 6826: Desquamative interstitial pneumonitis
- DC 6827: Pulmonary alveolar proteinosis
- DC 6828: Eosinophilic granuloma of lung
- DC 6830: Radiation-induced pulmonary pneumonitis and fibrosis
- DC 6831: Hypersensitivity pneumonitis (extrinsic allergic alveolitis)
- DC 6832: Pneumoconiosis (silicosis, anthracosis, etc.)
- DC 6833: Asbestosis
DC 6830: Radiation-Induced Pulmonary Pneumonitis And Fibrosis
Diagnostic code 6830 addresses Radiation-induced pulmonary pneumonitis and fibrosis. Read its specific instructions together with any shared formula, notes and linked provisions. These criteria describe evaluation after the applicable entitlement requirements are met; this reference does not diagnose a condition or determine a claim.
| Rating | |
|---|---|
| 6830 Radiation-induced pulmonary pneumonitis and fibrosis. | |
| 1 Review for entitlement to special monthly compensation under § 3.350 of this chapter. | |
Read the shared provisions referenced by this code: Interstitial Lung Formula.
What The Criteria Measure
- Does the decision identify diagnostic code 6830, and does the medical record describe the condition named by this code?
- Are the required clinical measurements, testing methods and any stated exceptions documented by a qualified clinician?
- Do records identify the treatment, procedure and relevant dates that the provision actually distinguishes?
- Have the code-specific notes and cross-references been read before comparing any listed evaluation?
Related Public DBQs
Editorial subject matches, not official VA code-to-form assignments. Read the form scope and clinician instructions.
Regulatory Cross-References
- DC 6825: Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis)
- DC 6826: Desquamative interstitial pneumonitis
- DC 6827: Pulmonary alveolar proteinosis
- DC 6828: Eosinophilic granuloma of lung
- DC 6829: Drug-induced pulmonary pneumonitis and fibrosis
- DC 6831: Hypersensitivity pneumonitis (extrinsic allergic alveolitis)
- DC 6832: Pneumoconiosis (silicosis, anthracosis, etc.)
- DC 6833: Asbestosis
DC 6831: Hypersensitivity Pneumonitis (Extrinsic Allergic Alveolitis)
Diagnostic code 6831 addresses Hypersensitivity pneumonitis (extrinsic allergic alveolitis). Read its specific instructions together with any shared formula, notes and linked provisions. These criteria describe evaluation after the applicable entitlement requirements are met; this reference does not diagnose a condition or determine a claim.
| Rating | |
|---|---|
| 6831 Hypersensitivity pneumonitis (extrinsic allergic alveolitis). | |
| 1 Review for entitlement to special monthly compensation under § 3.350 of this chapter. | |
Read the shared provisions referenced by this code: Interstitial Lung Formula.
What The Criteria Measure
- Does the decision identify diagnostic code 6831, and does the medical record describe the condition named by this code?
- Are the required clinical measurements, testing methods and any stated exceptions documented by a qualified clinician?
- Do records identify the treatment, procedure and relevant dates that the provision actually distinguishes?
- Have the code-specific notes and cross-references been read before comparing any listed evaluation?
Related Public DBQs
Editorial subject matches, not official VA code-to-form assignments. Read the form scope and clinician instructions.
Regulatory Cross-References
- DC 6825: Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis)
- DC 6826: Desquamative interstitial pneumonitis
- DC 6827: Pulmonary alveolar proteinosis
- DC 6828: Eosinophilic granuloma of lung
- DC 6829: Drug-induced pulmonary pneumonitis and fibrosis
- DC 6830: Radiation-induced pulmonary pneumonitis and fibrosis
- DC 6832: Pneumoconiosis (silicosis, anthracosis, etc.)
- DC 6833: Asbestosis
DC 6832: Pneumoconiosis (Silicosis, Anthracosis, Etc.)
Diagnostic code 6832 addresses Pneumoconiosis (silicosis, anthracosis, etc.). Read its specific instructions together with any shared formula, notes and linked provisions. These criteria describe evaluation after the applicable entitlement requirements are met; this reference does not diagnose a condition or determine a claim.
| Rating | |
|---|---|
| 6832 Pneumoconiosis (silicosis, anthracosis, etc.). | |
| 1 Review for entitlement to special monthly compensation under § 3.350 of this chapter. | |
Read the shared provisions referenced by this code: Interstitial Lung Formula.
What The Criteria Measure
- Does the decision identify diagnostic code 6832, and does the medical record describe the condition named by this code?
- Are the required clinical measurements, testing methods and any stated exceptions documented by a qualified clinician?
- Do records identify the treatment, procedure and relevant dates that the provision actually distinguishes?
- Have the code-specific notes and cross-references been read before comparing any listed evaluation?
Related Public DBQs
Editorial subject matches, not official VA code-to-form assignments. Read the form scope and clinician instructions.
Regulatory Cross-References
- DC 6825: Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis)
- DC 6826: Desquamative interstitial pneumonitis
- DC 6827: Pulmonary alveolar proteinosis
- DC 6828: Eosinophilic granuloma of lung
- DC 6829: Drug-induced pulmonary pneumonitis and fibrosis
- DC 6830: Radiation-induced pulmonary pneumonitis and fibrosis
- DC 6831: Hypersensitivity pneumonitis (extrinsic allergic alveolitis)
- DC 6833: Asbestosis
DC 6833: Asbestosis
Diagnostic code 6833 addresses Asbestosis. Read its specific instructions together with any shared formula, notes and linked provisions. These criteria describe evaluation after the applicable entitlement requirements are met; this reference does not diagnose a condition or determine a claim.
| Rating | |
|---|---|
| 6833 Asbestosis. | |
| 1 Review for entitlement to special monthly compensation under § 3.350 of this chapter. | |
Read the shared provisions referenced by this code: Interstitial Lung Formula.
What The Criteria Measure
- Does the decision identify diagnostic code 6833, and does the medical record describe the condition named by this code?
- Are the required clinical measurements, testing methods and any stated exceptions documented by a qualified clinician?
- Do records identify the treatment, procedure and relevant dates that the provision actually distinguishes?
- Have the code-specific notes and cross-references been read before comparing any listed evaluation?
Related Public DBQs
Editorial subject matches, not official VA code-to-form assignments. Read the form scope and clinician instructions.
Regulatory Cross-References
- DC 6825: Diffuse interstitial fibrosis (interstitial pneumonitis, fibrosing alveolitis)
- DC 6826: Desquamative interstitial pneumonitis
- DC 6827: Pulmonary alveolar proteinosis
- DC 6828: Eosinophilic granuloma of lung
- DC 6829: Drug-induced pulmonary pneumonitis and fibrosis
- DC 6830: Radiation-induced pulmonary pneumonitis and fibrosis
- DC 6831: Hypersensitivity pneumonitis (extrinsic allergic alveolitis)
- DC 6832: Pneumoconiosis (silicosis, anthracosis, etc.)
Interstitial Lung Formula
Referenced by DC 6825, DC 6826, DC 6827, DC 6828, DC 6829, DC 6830, DC 6831, DC 6832, DC 6833. Apply only as each code directs, including its conditions and exceptions.
| Rating | |
|---|---|
| General Rating Formula for Interstitial Lung Disease (diagnostic codes 6825 through 6833): | |
| Forced Vital Capacity (FVC) less than 50-percent predicted, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption with cardiorespiratory limitation, or; cor pulmonale or pulmonary hypertension, or; requires outpatient oxygen therapy | 100 |
| FVC of 50- to 64-percent predicted, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum exercise capacity of 15 to 20 ml/kg/min oxygen consumption with cardiorespiratory limitation | 60 |
| FVC of 65- to 74-percent predicted, or; DLCO (SB) of 56- to 65-percent predicted | 30 |
| FVC of 75- to 80-percent predicted, or; DLCO (SB) of 66- to 80-percent predicted | 10 |
| 1 Review for entitlement to special monthly compensation under § 3.350 of this chapter. | |
Shared Rules And Regulatory Context
Context provisions do not create an additional evaluation automatically assigned to every condition.
Related Guides
Official Sources
Last verified 2026-10-25. Source publication or legal effective dates are shown separately where available.
Check The Source. Get Accredited Help.
Use this resource to understand published information. VA and the official decision control individual benefits.